Tag: Hatch-Waxman Act

30-Month Stay: How Litigation Delays Generic Drug Approval

The 30-month stay under the Hatch-Waxman Act delays generic drug approval by freezing FDA action during patent lawsuits. While meant to protect innovation, it's often used to extend monopolies, costing patients billions annually.